Revolutionizing Drug Discovery with NAMs and AI Technology

At NAMina Bio, we believe the future of biomedical innovation lies in rethinking how science connects to life. Our mission is to transform drug discovery through the integration of New Approach Methodologies (NAMs) and artificial intelligence, creating a more predictive, humane, and efficient framework for developing tomorrow’s therapies.

We are building an AI-enhanced, human-based discovery platform that brings together patient-derived organoids, organ-on-a-chip systems, and data-driven predictive modeling. This fusion of technologies will enable high-throughput, human-relevant screening for both drug candidates and natural compounds—reducing dependence on animal testing while increasing translational accuracy.

NAMina Bio aims to develop multiscale human avatars that replicate patient-specific biology across molecular and tissue levels. These living avatars will allow researchers to anticipate real-world therapeutic outcomes more effectively than ever before, accelerating progress from the laboratory to the clinic.

Our broader goal is to democratize precision medicine—making personalized, ethical research tools available to scientists, startups, and institutions worldwide. By aligning with the FDA’s Modernization Act 2.0 and contributing to regulatory science through NAMs, NAMina Bio is helping to build a global framework where innovation and responsibility move hand in hand.

At the heart of our mission is a simple conviction: that progress in medicine must reflect both scientific intelligence and moral intelligence. Through our commitment to NAMs, AI technology, and ethical principles, NAMina Bio is charting a path toward a future where precision oncology and humane science converge—delivering smarter, safer, and more compassionate healthcare for all.